// Biotech and Pharma Therapeutics
Bar-Ilan University and Sheba Medical Center to Launch $120M Biotech Research Institute
September 17, 2025 / biotech innovation / personalized medicine / medical robotics / translational research / Israeli healthcare
The Future of Healthcare Is in Your Pocket: How AI and Smartphones Are Transforming Patient Care
September 17, 2025 / AI healthcare / digital health / remote monitoring / chronic disease prevention / smartphone diagnostics
AI-powered smartphones are transforming patient care by enabling real-time health monitoring, medication adherence, and early detection of chronic diseases—offering scalable, proactive solutions to reduce disparities, lower costs, and improve outcomes across underserved and high-risk populations.
BD expands Class I recall to cover 15 more Alaris pump infusion sets
September 17, 2025 / infusion pump recall / Alaris safety / BD medical devices / patient risk management / FDA device alerts
BD expanded a Class I recall to include 15 discontinued Alaris infusion sets due to risks of inaccurate medication delivery, posing serious threats to vulnerable patients. Healthcare providers are urged to use alternatives or apply enhanced monitoring when necessary.
A Pathway Towards Practice Optimization and Revenue Growth
September 17, 2025 / AI documentation / EHR integration / clinician burnout / medical billing efficiency / healthcare automation
Deeply integrated AI scribe solutions embedded in EHR workflows streamline documentation, reduce burnout, accelerate reimbursements, and enhance clinical focus—transforming a major administrative burden into a revenue-generating asset for healthcare practices.
Major health insurer group says members will continue to cover vaccines, a step that may ease anxiety over access
September 17, 2025 / vaccine access / health insurance coverage / hepatitis B newborns / immunization policy / preventive healthcare
America’s Health Insurance Plans affirmed continued coverage of all CDC-recommended vaccines, including hepatitis B for newborns, regardless of upcoming advisory changes—helping ensure vaccine access and prevent potential resurgence of preventable diseases like liver cancer and hepatitis.
// 4th Industrial Revolution
Implantable device helps stabilize blood pressure in spinal cord injury patients
September 17, 2025 / spinal cord injury / blood pressure stability / neurostimulation therapy / implantable device / SCI treatment
A novel implantable neurostimulation device restores stable blood pressure in spinal cord injury patients, reducing dangerous hypotension and hypertension episodes through targeted spinal cord stimulation—offering improved safety, cognitive clarity, and energy in a globally validated clinical breakthrough.
Inside Duke’s Approach to Building and Buying AI Tools
September 17, 2025 / AI in healthcare / clinician burnout / patient monitoring / task automation / nursing workforce
Duke University Health System leverages both in-house and vendor AI tools to automate administrative tasks, reduce clinician burden, and detect patient deterioration early—enhancing care delivery amid workforce shortages and growing demand for healthcare services.
Virtual Clinical Trials: Mayo Clinic’s AI-Powered Solution to Accelerate Heart Failure Drug Discovery
September 17, 2025 / heart failure treatment / AI drug discovery / virtual clinical trials / drug repurposing / Mayo Clinic innovation
Mayo Clinic is using AI-driven virtual clinical trials and real-world data to accelerate heart failure drug discovery—particularly via drug repurposing—reducing time, cost, and risk while emulating traditional trials with high predictive accuracy.
Zoom Unveils AI Companion 3.0 and Agentic AI Innovations
September 17, 2025 / healthcare collaboration / AI automation / clinical communication tools / virtual healthcare support / real-time translation
Zoom’s AI Companion 3.0 introduces agentic AI across its ecosystem, streamlining healthcare collaboration with advanced meeting prep, real-time translation, and context-aware insights—enabling clinicians and administrators to reduce administrative load and improve cross-functional communication.
ATA Launches Digital Infrastructure Score to Map U.S. Virtual Care Readiness
September 17, 2025 / virtual care readiness / digital health equity / broadband access / rural healthcare infrastructure / telehealth expansion
The ATA’s enhanced Digital Infrastructure Score maps U.S. communities’ readiness for virtual care by analyzing broadband access, speed, device availability, and affordability—guiding healthcare investments, policy planning, and equitable digital health adoption, especially in underserved and rural areas.
// Business & Markets
Arvinas and Pfizer to out-license breast cancer drug vepdegestrant
September 17, 2025 / breast cancer therapy / ESR1 mutation treatment / vepdegestrant licensing / Arvinas Pfizer partnership / PROTAC drug development
Arvinas and Pfizer will out-license vepdegestrant, an investigational treatment for ESR1-mutant, ER+/HER2- advanced breast cancer, currently under FDA review. The strategic shift aligns with Arvinas’ cost-cutting measures and ongoing development of other PROTAC-based oncology candidates.
Lōvu Health Rakes In $8M for Maternal Health Platform
September 17, 2025 / maternal health platform / AI pregnancy care / digital prenatal monitoring / postpartum support tools / maternal mortality prevention
Lōvu Health raised $8M to enhance its AI-powered maternal health platform, enabling real-time monitoring, early intervention, and personalized care from conception through two years postpartum—addressing maternal care deserts and aiming to reduce preventable maternal mortality in the U.S.
ArsenalBio lays off 50% of staff in pivot from early-stage research
September 17, 2025 / CAR-T cell therapy / renal cell carcinoma / biotech layoffs 2025 / clinical-stage transition / ArsenalBio restructuring
ArsenalBio is cutting 50% of its workforce as it shifts from early-stage research to clinical development, prioritizing lead CAR-T asset AB-2100 for renal cell carcinoma while maintaining its collaboration with Bristol Myers Squibb on solid tumor cell therapies.
GSK Plans to Spend $30B on U.S. Manufacturing and R&D Infrastructure Over the Next 5 Years
September 17, 2025 / GSK investment USA / pharmaceutical manufacturing / biologics production AI / clinical trial expansion / drug supply chain
GSK will invest $30 billion in U.S. manufacturing and R&D over five years, expanding biologics production, AI integration, and clinical trial capacity—strengthening domestic drug supply, innovation, and creating hundreds of skilled jobs amid growing emphasis on U.S.-based pharma infrastructure.
Imagine Pediatrics Secures $67M Funding to Expand Care for Children with Special Needs
September 17, 2025 / pediatric special needs / value-based care / virtual pediatric care / chronic condition management / behavioral health support
Imagine Pediatrics raised $67M to expand its 24/7 tech-enabled, value-based care model for children with special health care needs—integrating medical, behavioral, and social services to reduce hospitalizations, improve outcomes, and address chronic and complex pediatric conditions nationwide.
// Legal & Regulatory
FDA warns on unauthorized blood pressure, infant monitoring devices
September 17, 2025 / FDA warning devices / infant vital monitoring / blood pressure accuracy / unauthorized health tech / medical device safety
The FDA warns against using unauthorized over-the-counter blood pressure and infant monitoring devices, citing risks of inaccurate readings that may delay or misguide treatment. Patients are urged to verify FDA authorization through official databases before using such devices.
Device maker that helped UnitedHealth collect billions settles fraud claims with DOJ
September 17, 2025 / healthcare fraud settlement / Medicare Advantage screening / QuantaFlo device lawsuit / peripheral artery disease / DOJ medical device enforcement
Semler Scientific will pay nearly $30M to settle DOJ fraud claims involving its QuantaFlo device, widely used by Medicare Advantage insurers like UnitedHealth and Aetna for peripheral artery disease screening; major client rollbacks are expected to halve revenue.
Pharma tells Scotland how to court investment amid UK life sciences turmoil
September 17, 2025 / clinical trial access / pharma investment Scotland / ABPI life sciences / UK drug pricing / research infrastructure innovation
Amid U.K. life sciences uncertainty, the ABPI urges Scotland to attract pharma investment by streamlining clinical trial approvals, reinvesting study revenues, improving access to standard-of-care medicines, and adopting innovative pricing models to foster a globally competitive R&D ecosystem.
How a Legal Settlement and New Rival Test Could Influence Natera’s (NTRA) Competitive Strategy
September 14, 2025 / molecular diagnostics competition / Signatera oncology test / multi-cancer detection / clinical trial reimbursement / Natera growth strategy
Natera’s $8.25M legal settlement and new competition from Exact Sciences’ multi-cancer detection test introduce uncertainty but don’t alter its growth strategy centered on expanding Signatera’s clinical adoption and reimbursement, particularly through trials like ARCHER.
Ionis, Arrowhead file dueling patent lawsuits over genetic-disorder drug
Ionis and Arrowhead have filed dueling lawsuits over alleged patent infringement related to treatments for familial chylomicronemia syndrome (FCS), following FDA approval of Ionis’ Tryngolza and Arrowhead’s application for its competing drug, plozasiran.
// Research & Development
Lilly’s Mounjaro shows strong results in pediatric diabetes trial
September 17, 2025 / pediatric type 2 diabetes / Mounjaro clinical trial / tirzepatide efficacy / A1C reduction children / Eli Lilly diabetes therapy
Eli Lilly’s Mounjaro (tirzepatide) significantly improved A1C and reduced BMI in children with type 2 diabetes in the Phase 3 SURPASS-PEDS trial, supporting regulatory submissions for pediatric use and expanding its role in diabetes management.
Goodbye colonoscopy? Simple stool test detects 90% of colorectal cancers
September 17, 2025 / colorectal cancer detection / stool test screening / gut microbiome biomarkers / noninvasive cancer test / machine learning diagnostics
University of Geneva researchers used machine learning on subspecies-level gut microbiome data to develop a stool test that detects 90% of colorectal cancers, offering a less invasive, cost-effective alternative to colonoscopy for early cancer screening.
Rogue DNA rings may be the secret spark driving deadly brain cancer
September 17, 2025 / glioblastoma early detection / ecDNA brain cancer / rogue DNA glioblastoma / brain tumor biomarkers / glioblastoma treatment research
Extrachromosomal DNA (ecDNA) rings may drive glioblastoma’s aggressive growth and resistance, emerging before tumor formation. This discovery offers potential for early detection and intervention, presenting a promising avenue to combat one of the deadliest brain cancers.
ARTHEx raises $87 million in upsized series B to advance RNA therapy
September 17, 2025 / RNA therapy DM1 / myotonic dystrophy treatment / microRNA23b inhibitor / ARTHEx ATX-01 funding / genetic muscle disorder
ARTHEx raised $87 million in Series B funding to advance ATX-01, an RNA therapy targeting microRNA23b to restore MBNL protein function in myotonic dystrophy type 1 (DM1), aiming to address the disease’s root cause. Early data expected 2026.
CRISPR-based tongue swab test shows promise for tuberculosis detection
September 17, 2025 / CRISPR TB detection / tongue swab test / noninvasive TB screening / community health diagnostics / tuberculosis point-of-care
Tulane researchers developed a CRISPR-based tongue swab test that detects tuberculosis with high sensitivity, offering a noninvasive, rapid, and scalable alternative to sputum testing—potentially transforming community-based screening in low-resource and asymptomatic populations.
// Politics
Fired CDC director says RFK Jr. aims to change childhood vaccine schedule
September 17, 2025 / childhood vaccine schedule / CDC leadership resignations / RFK Jr. vaccine policy / public health controversy / vaccine guideline changes
Former CDC Director Susan Monarez testified that Health Secretary RFK Jr. plans to alter the childhood vaccine schedule without sufficient scientific backing, sparking high-level resignations and raising concerns over politicization of evidence-based public health policy.
3 key takeaways from the Senate hearing on CDC director’s firing and RFK Jr.’s vaccine agenda
September 17, 2025 / CDC leadership resignations / RFK Jr. vaccine agenda / politicized public health / childhood immunization changes / Senate CDC hearing
Former CDC leaders testified that RFK Jr. is politicizing public health, suppressing scientific input, and planning to overhaul the childhood vaccine schedule—moves they warn could undermine evidence-based policy and worsen national health outcomes.
Fear and politics pervade Kennedy’s CDC, former leaders testify
September 17, 2025 / CDC leadership crisis / scientific integrity erosion / RFK Jr. public health / political interference CDC / public health infrastructure
Former CDC leaders testified that political interference under RFK Jr. has created a climate of fear and undermined scientific integrity, weakening the agency’s ability to support national and global public health efforts.
What former CDC officials will say at today’s Senate hearing
September 17, 2025 / CDC political interference / RFK Jr. testimony / public health integrity / science vs politics / Senate CDC hearing
Former CDC officials are expected to testify that RFK Jr. has politicized the agency, prioritizing ideology over science—posing a serious threat to evidence-based public health policy and the CDC’s ability to protect American health.
Indian pharma seeks exemption from new wave of US tariffs
September 17, 2025 / US pharma tariffs / Indian generic drugs / drug supply chain risk / medicine import duties / healthcare cost impact
Indian pharmaceutical companies are urging exemption from potential U.S. tariffs under a national security probe, warning such duties could disrupt global generic drug supply chains, increase medication costs for Americans, and threaten access to affordable essential medicines.